ABSTRACT The paradoxical bronchoconstriction observed with commercially available isotonic ipratropium bromide nebuliser solution (Atrovent) in patients with asthma results from an adverse reaction to the preservatives, benzalkonium chloride and ethylenediaminetetra-acetic acid (EDTA). The airway response to inhaled Atrovent and preservative free ipratropium bromide nebuliser solutions has been examined in a double blind study. On separate occasions 30 asthmatic subjects inhaled 2 ml of the solutions and airway calibre was measured in terms of FEV, for 45 minutes.
Introduction
Ipratropium bromide (Atrovent) administered for inhalation by pressurised metered dose aerosol has found wide use for the treatment of reversible obstructive airways disease. The drug is also available as a solution for nebulisation in patients with severe airflow limitation, though occasional paradoxical bronchoconstriction has been reported.' When the bronchoconstriction had been shown to be largely accounted for by the hypotonicity of the original nebulised solution4 this was reformulated as an isotonic solution. Despite this change occasional reports of bronchoconstriction still occur. 5 In a single case study Patel et al5 suggested that bronchoconstriction with ipratropium bromide occurred as an idiosyncratic response to the bromide ion, but in a controlled study in patients who developed bronchoconstriction with hypotonic ipratropium bromide and sodium bromide administration of the solutions in the isotonic form failed to produce this response.6 In a further double blind, placebo controlled study in asthmatic subjects we have shown that both benzalkonium chloride and ethyl-enediaminetetra-acetic acid (EDTA), present in isotonic Atrovent as bacteriostatic and stabilising agents, cause bronchoconstriction.7 Benzalkonium chloride caused bronchoconstriction at the concentration present in the nebuliser solution of 0 25 g/l, whereas EDTA caused bronchoconstriction only at concentrations more than twice that present in the nebuliser solution (0 5 g/l). In this study about a quarter of asthmatic subjects who inhaled Atrovent from a starting volume of 4 ml (that is, I mg ipratropium bromide) developed immediate bronchoconstriction with a fall in forced expiratory volume in one second (FEV,) of more than 20% from baseline. When these subjects inhaled only isotonic preservative free ipratropium bromide bronchodilatation occurred. We have now investigated the effect of the maximum single dose ofisotonic Atrovent recommended by the manufacturer (2 ml-that is, 0 5 mg ipratropium bromide) on airway calibre in patients with asthma and chronic bronchitis and compared its bronchodilator effect with that of preservative free ipratropium bromide.
Methods

PATIENTS
Thirty patients took part in the study and their characteristics are described in table 1 . All had 446 Comparison of the efficacy ofpreservativefree ipratropium bromide and Atrovent nebuliser solution 1, table 2 ), the FEV, remained below the initial baseline value 45 minutes after inhalation in six subjects. After inhalation of 2 ml preservative free ipratropium bromide one subject showed an initial fall in FEV, of 19%, which returned to within 2% of baseline by 2 minutes. None of the other subjects showed a fall in FEV, of more than 10%. All subjects subsequently achieved bronchodilatation with this preparation (fig 1) . The speed of onset and the degree of bronchodilatation was greater after preservative free ipratropium bromide than after Atrovent (fig 1,  table 2 ). (fig 1) . We have previously shown that both benzalkonium chloride and EDTA may cause bronchoconstriction in patients with asthma, with a response lasting at least 45 minutes. In Atrovent therefore the bronchoconstrictor effects of the preservatives are likely to be competing with the bronchoditator-action of ipratropium bromide, in some subjects the initial response being sufficient to cause bronchoconstriction.
A further insight into the possible mechanism or mechanisms by which benzalkonium chloride and EDTA may cause bronchoconstriction comes from observing the influence of atopy on the airways responses (fig 2) . The bronchodilatation observed after inhalation of preservative free ipratropium bromide was similar in the two groups; in response to Atrovent the atopic subjects achieved less bronchodilatation than non-atopic subjects, though the difference was not significant. A fall in FEV, of20% or more was experienced by three of the 13 atopic subjects after Atrovent, but only transiently in two of the 17 non-atopic subjects. This reaction could not be Table 3 Comparison ofairway responses (means with standard errors in parentheses) to A trovent in atopic and non-atopic subjects 449 450 sodium cromoglycate completely abolished the bronchoconstriction, suggesting that the immediate airway response may be mediated through a mast cell dependent mechanism. A similar mechanism might have been responsible for a recent case in which nebulised beclomethasone diproprionate containing benzalkonium chloride, in a concentration of 0-2 g/l, appeared to produce bronchoconstriction in asthmatic patients seven months after starting treatment. 7 Bronchoconstriction by EDTA is thought to occur via a direct contractile effect on airway smooth muscle through calcium chelation. '8 Although the concentration of EDTA required to produce bronchoconstriction under challenge conditions was at least twice that present in Atrovent nebuliser solution, this agent has been shown to increase non-specific bronchial responsiveness in Basenji greyhound dogs.'8 An interaction between benzalkonium chloride and EDTA is therefore possible, with EDTA enhancing airway smooth muscle responsiveness to spasmogenic mediators released from mast cells by benzalkonium chloride.
We conclude that the currently marketed Atrovent nebuliser solution containing preservatives can produce bronchoconstriction in some patients, even when administered in the manufacturers' recommended dose. Bronchoconstriction was not observed when the two preservatives were removed from the solution, and preservative free ipratropium bromide proved to be considerably more effective as a bronchodilator agent than Atrovent. A recent study'9 has reported an inverse relation between the incidence of bacterial contamination of nebuliser solutions and the presence of antibacterial agents in the solution, so removal of these preservatives might result in an increased incidence of bacterial contamination. Contamination would be less likely ifthe solution were prepared under sterile conditions in unit dose vials.
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